Abstract: A single-piece tray for hydroponic cultivation, composed of a plastic material shaped to define identical cultivation cells inside the tray. Each cultivation cell has: a housing defining a raised plane and configured to house a bulb or seedling to be cultivated, with a hole dimensioned to support the bulb or seedling without letting it fall through, while allowing its roots to protrude below the tray; a buoyant portion, defining a lowered plane intended to sink below a waterline, and delimited by side walls, each buoyant portion defining: a bottomside with a first height, a waterline zone with a second height, a topside with a third height; the sum of the first, second and third heights corresponding to the height of the side walls which connect the raised plane to the lowered plane. The side walls forming a channel.

Abstract: Disclosed are compounds having the formula (I): wherein the R1, R2, R3, X, Y, A, L, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Abstract: Disclosed are compounds of Formula (I) wherein the R, R1, R2, R3, X, Y, A, Q, E, and G are defined herein. These compounds bind to aspartic proteases to inhibit their activity and are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also disclosed are methods of use of the compounds of Formula I for ameliorating or treating aspartic protease related disorders in a subject in need thereof.

Abstract: Disclosed are compounds according to Formula I: wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.

Abstract: A compound of formula (I) wherein: R is a group selected from: A-B is a bivalent radical of formula (v), (vi) or (vii) —CH?C(R11)—??(v) —C(R10)?CH— or??(vi) —C(R12)(R10)—C(R11)(R13)—??(viii) and all other variables are as defined herein or a pharmaceutically acceptable salt or solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

Abstract: A compound of formula (I) wherein: R is a group selected from: A-B is a bivalent radical of formula (v), (vi) or (vii) —CH?C(R11)—??(v) —C(R10)?CH— or??(vi) —C(R12)(R10)—C(R11)(R13)—??(viii) and all other variables are as defined herein or a pharmaceutically acceptable salt or solvate thereof, process for their preparation and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.